Cargando…

Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson’s disease

BACKGROUND: Mitochondrial dysfunction, oxidative stress and their interplay are core pathological features of Parkinson’s disease. In dopaminergic neurons, monoamines and their metabolites provide an additional source of reactive free radicals during their breakdown by monoamine oxidase or auto-oxid...

Descripción completa

Detalles Bibliográficos
Autores principales: Baranyi, Mária, Porceddu, Pier Francesca, Gölöncsér, Flóra, Kulcsár, Szabina, Otrokocsi, Lilla, Kittel, Ágnes, Pinna, Annalisa, Frau, Lucia, Huleatt, Paul B., Khoo, Mui-Ling, Chai, Christina L. L., Dunkel, Petra, Mátyus, Peter, Morelli, Micaela, Sperlágh, Beáta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4711075/
https://www.ncbi.nlm.nih.gov/pubmed/26758813
http://dx.doi.org/10.1186/s13024-015-0067-y
_version_ 1782409913926942720
author Baranyi, Mária
Porceddu, Pier Francesca
Gölöncsér, Flóra
Kulcsár, Szabina
Otrokocsi, Lilla
Kittel, Ágnes
Pinna, Annalisa
Frau, Lucia
Huleatt, Paul B.
Khoo, Mui-Ling
Chai, Christina L. L.
Dunkel, Petra
Mátyus, Peter
Morelli, Micaela
Sperlágh, Beáta
author_facet Baranyi, Mária
Porceddu, Pier Francesca
Gölöncsér, Flóra
Kulcsár, Szabina
Otrokocsi, Lilla
Kittel, Ágnes
Pinna, Annalisa
Frau, Lucia
Huleatt, Paul B.
Khoo, Mui-Ling
Chai, Christina L. L.
Dunkel, Petra
Mátyus, Peter
Morelli, Micaela
Sperlágh, Beáta
author_sort Baranyi, Mária
collection PubMed
description BACKGROUND: Mitochondrial dysfunction, oxidative stress and their interplay are core pathological features of Parkinson’s disease. In dopaminergic neurons, monoamines and their metabolites provide an additional source of reactive free radicals during their breakdown by monoamine oxidase or auto-oxidation. Moreover, mitochondrial dysfunction and oxidative stress have a supraadditive impact on the pathological, cytoplasmic accumulation of dopamine and its subsequent release. Here we report the effects of a novel series of potent and selective MAO-B inhibitory (hetero)arylalkenylpropargylamine compounds having protective properties against the supraadditive effect of mitochondrial dysfunction and oxidative stress. RESULTS: The (hetero)arylalkenylpropargylamines were tested in vitro, on acute rat striatal slices, pretreated with the complex I inhibitor rotenone and in vivo, using the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced acute, subchronic, and chronic experimental models of Parkinson’s disease in mice. The compounds exhibited consistent protective effects against i) in vitro oxidative stress induced pathological dopamine release and the formation of toxic dopamine quinone in the rat striatum and rescued tyrosine hydroxylase positive neurons in the substantia nigra after rotenone treatment; ii) in vivo MPTP-induced striatal dopamine depletion and motor dysfunction in mice using acute and subchronic, delayed application protocols. One compound (SZV558) was also examined and proved to be protective in a chronic mouse model of MPTP plus probenecid (MPTPp) administration, which induces a progressive loss of nigrostriatal dopaminergic neurons. CONCLUSIONS: Simultaneous inhibition of MAO-B and oxidative stress induced pathological dopamine release by the novel propargylamines is protective in animal models and seems a plausible strategy to combat Parkinson’s disease. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13024-015-0067-y) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4711075
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47110752016-01-14 Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson’s disease Baranyi, Mária Porceddu, Pier Francesca Gölöncsér, Flóra Kulcsár, Szabina Otrokocsi, Lilla Kittel, Ágnes Pinna, Annalisa Frau, Lucia Huleatt, Paul B. Khoo, Mui-Ling Chai, Christina L. L. Dunkel, Petra Mátyus, Peter Morelli, Micaela Sperlágh, Beáta Mol Neurodegener Research Article BACKGROUND: Mitochondrial dysfunction, oxidative stress and their interplay are core pathological features of Parkinson’s disease. In dopaminergic neurons, monoamines and their metabolites provide an additional source of reactive free radicals during their breakdown by monoamine oxidase or auto-oxidation. Moreover, mitochondrial dysfunction and oxidative stress have a supraadditive impact on the pathological, cytoplasmic accumulation of dopamine and its subsequent release. Here we report the effects of a novel series of potent and selective MAO-B inhibitory (hetero)arylalkenylpropargylamine compounds having protective properties against the supraadditive effect of mitochondrial dysfunction and oxidative stress. RESULTS: The (hetero)arylalkenylpropargylamines were tested in vitro, on acute rat striatal slices, pretreated with the complex I inhibitor rotenone and in vivo, using the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced acute, subchronic, and chronic experimental models of Parkinson’s disease in mice. The compounds exhibited consistent protective effects against i) in vitro oxidative stress induced pathological dopamine release and the formation of toxic dopamine quinone in the rat striatum and rescued tyrosine hydroxylase positive neurons in the substantia nigra after rotenone treatment; ii) in vivo MPTP-induced striatal dopamine depletion and motor dysfunction in mice using acute and subchronic, delayed application protocols. One compound (SZV558) was also examined and proved to be protective in a chronic mouse model of MPTP plus probenecid (MPTPp) administration, which induces a progressive loss of nigrostriatal dopaminergic neurons. CONCLUSIONS: Simultaneous inhibition of MAO-B and oxidative stress induced pathological dopamine release by the novel propargylamines is protective in animal models and seems a plausible strategy to combat Parkinson’s disease. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13024-015-0067-y) contains supplementary material, which is available to authorized users. BioMed Central 2016-01-13 /pmc/articles/PMC4711075/ /pubmed/26758813 http://dx.doi.org/10.1186/s13024-015-0067-y Text en © Baranyi et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Baranyi, Mária
Porceddu, Pier Francesca
Gölöncsér, Flóra
Kulcsár, Szabina
Otrokocsi, Lilla
Kittel, Ágnes
Pinna, Annalisa
Frau, Lucia
Huleatt, Paul B.
Khoo, Mui-Ling
Chai, Christina L. L.
Dunkel, Petra
Mátyus, Peter
Morelli, Micaela
Sperlágh, Beáta
Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson’s disease
title Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson’s disease
title_full Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson’s disease
title_fullStr Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson’s disease
title_full_unstemmed Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson’s disease
title_short Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson’s disease
title_sort novel (hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of parkinson’s disease
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4711075/
https://www.ncbi.nlm.nih.gov/pubmed/26758813
http://dx.doi.org/10.1186/s13024-015-0067-y
work_keys_str_mv AT baranyimaria novelheteroarylalkenylpropargylaminecompoundsareprotectiveintoxininducedmodelsofparkinsonsdisease
AT porceddupierfrancesca novelheteroarylalkenylpropargylaminecompoundsareprotectiveintoxininducedmodelsofparkinsonsdisease
AT goloncserflora novelheteroarylalkenylpropargylaminecompoundsareprotectiveintoxininducedmodelsofparkinsonsdisease
AT kulcsarszabina novelheteroarylalkenylpropargylaminecompoundsareprotectiveintoxininducedmodelsofparkinsonsdisease
AT otrokocsililla novelheteroarylalkenylpropargylaminecompoundsareprotectiveintoxininducedmodelsofparkinsonsdisease
AT kittelagnes novelheteroarylalkenylpropargylaminecompoundsareprotectiveintoxininducedmodelsofparkinsonsdisease
AT pinnaannalisa novelheteroarylalkenylpropargylaminecompoundsareprotectiveintoxininducedmodelsofparkinsonsdisease
AT fraulucia novelheteroarylalkenylpropargylaminecompoundsareprotectiveintoxininducedmodelsofparkinsonsdisease
AT huleattpaulb novelheteroarylalkenylpropargylaminecompoundsareprotectiveintoxininducedmodelsofparkinsonsdisease
AT khoomuiling novelheteroarylalkenylpropargylaminecompoundsareprotectiveintoxininducedmodelsofparkinsonsdisease
AT chaichristinall novelheteroarylalkenylpropargylaminecompoundsareprotectiveintoxininducedmodelsofparkinsonsdisease
AT dunkelpetra novelheteroarylalkenylpropargylaminecompoundsareprotectiveintoxininducedmodelsofparkinsonsdisease
AT matyuspeter novelheteroarylalkenylpropargylaminecompoundsareprotectiveintoxininducedmodelsofparkinsonsdisease
AT morellimicaela novelheteroarylalkenylpropargylaminecompoundsareprotectiveintoxininducedmodelsofparkinsonsdisease
AT sperlaghbeata novelheteroarylalkenylpropargylaminecompoundsareprotectiveintoxininducedmodelsofparkinsonsdisease